Eskayef Pharmaceuticals Ltd.
TypePrivate Limited
IndustryPharmaceutical Industry
Founded1990 (1990)
FounderLatifur Rahman
HeadquartersPlot: 82, Road: 14 Block - B, Banani,
Dhaka
,
Bangladesh
Key people
Simeen Rahman (Managing Director & CEO)
RevenueIncreaseUS$300 million
ParentTranscom Group
Websiteskfbd.com

Eskayef Pharmaceuticals Ltd., also known as SK+F, is a pharmaceutical company in Bangladesh. It belongs to the Transcom Group.[1][2] Simeen Rahman is the Managing Director and CEO of the company.[2][3]

History

Eskayef Bangladesh Ltd., a successor of Smith, Kline & French in Bangladesh, was acquired by Transcom in 1990.[2] According to an IMS report, the company was among the top six pharmaceutical companies operating in Bangladesh in terms of sales in 2021.[4] By 2021, it exported finished products to 65 countries.[2] The company was renamed Eskayef Pharmaceuticals Limited in January 2017.[5]

Products

The company is engaged in the manufacture and marketing of a wide range of therapeutic drugs, bulk pellets and animal health and nutrition products[6] including the oral anti covid medication Molnupiravir[7] & Nirmatrelvir co-packaged with Ritonavir and injectable Remdesivir.

References

  1. ↑ Iqbal, Farah K. (2016-09-19). "What makes the market tick?". Dhaka Tribune (Op-ed). Retrieved 2016-10-03.
  2. 1 2 3 4 "Eskayef sales jump manifold". The Daily Star. 2015-12-29. Retrieved 2016-10-03.
  3. ↑ "'I am the brand'". Prothom Alo. Retrieved 2016-10-03.
  4. ↑ Akter, Sayeda (2009-08-23). "Pharma industry set for expansion". The Daily Star. Retrieved 2016-10-03.
  5. ↑ "Eskayef pledges to conquer odds with courage". The Daily Star. 2017-01-24.
  6. ↑ "Eskayef beats rivals in sales growth". The Daily Star. 2012-01-26.
  7. ↑ "Beximco, Eskayef to produce Covid drug". businesspostbd.com. Retrieved 2021-11-10.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.